Human epidermal Langerhans cells (LCs) can coordinate both immunogenic and tolerogenic immune responses, creating an attractive opportunity for immunomodulation strategies. To investigate transcriptional determinants of human primary LC tolerance we applied single cells RNA-sequencing combined with extensive functional analysis. Unsupervised clustering of single cell transcriptomes indicated that steady-state LC populations exist in a spectrum of immune activation between two states: immunocompetent and immature, distinguishable by high or low CD86 expression, respectively. Suprisingly, LC immunompetency was critical for the efficient induction of regulatory T cells during co-culture assays with naïve CD4+ T cells and expansion of autologous memory T cells. Consistently, LC tolerogenic potential was significantly enhanced upon migration from the epidermis. Transcriptional programmes underpinning LC immunocompetency, with increased expression of dendritic cell activation markers (CD83, HLA-DRA and CCR7), were complemented with expression of tolerogenic markers (IDO1, LGALS1 and AHR) in migrated LC. Using protein expression analysis and perturbation with inhibitors, we confirmed the role of IDO1 as a key regulator of LC tolerogenic responses induced during LC migration, identified AHR as a potential component of IDO1-regulatory feedback loop, and demonstrated LC-mediated tolerance can be modulated through treatment with dexamethasone, indicating an opportunity for targeted therapeutic interventions in inflammatory skin disease.
Introduction
Langerhans cells (LCs) reside in the epidermis as a dense network of immune system sentinels, capable of initiating potent immune responses to cutaneous pathogens and neoplastic cells 1, 2 . As a first line of the cutaneous immune defence system, LCs are uniquely specialised at sensing the environment and extend dendrites through intercellular tight junctions to gain access to the outermost part of the skin, the stratum corneum, so that rapid responses can be initiated if a dangerous pathogen is encountered 3 . We and others have shown that LCs are highly capable of priming and augmenting CD4 T cell responses and can induce CD8 T cell activation via antigen cross presentation more effectively than CD11c+, CD141+, CD141-and CD14+ dermal DCs 4, 5, 6 . However, in the context of infection, LCs can be surprisingly inefficient; LCs fail to induce cytotoxic T cell in response to herpes simplex 1 virus and in the context of Leishmania major infection, ablation of LCs reduced the number of activated Treg cells and aided clearance of the disease, therefore questioning the role of LC in immunogenic responses to pathogenic stimuli 7, 8 .
In contrast, during steady-state (non-dangerous) conditions, LCs selectively induce the activation and proliferation of skin-resident regulatory T cells 9,10 that prevent unwanted immune-mediated reactions. This key role of LCs in the maintenance of cutaneous and systemic homeostasis has been confirmed in many experimental systems. Using a mouse model for investigating LC tolerance, antigen processing and presentation of the keratinocyte protein desmoglein (Dsg3) resulted in efficient regulatory T cell (Treg) induction, whilst ablation of LCs led to increased autoimmunity 11 . LC migration from the epidermis is constantly observed during steadystate and transport of self-antigen derived from melanin to skin draining lymph nodes results in no abnormal inflammatory disease, nor does the rate of transport change during induced inflammatory conditions 12, 13, 14 . In a mouse model of autoimmune encephalomyelitis, migratory skin LCs and not resident lymph DCs are required for the induction of Foxp3+ Tregs 15 . Epicutaneous delivery of OVA to OVA-sensitised mice and peanut protein to peanut-sensitised mice results in uptake and processing by skin DC and LC, but repeat exposure results in fewer inflammatory responses and an increase in Treg cells 16, 17 . Similarily, LCs mediate murine tolerance during sensitisation by the hapten DNTB and is reliant on the presence of Tregs 18 .
While LC-induced tolerance appears to be key to cutaneous immune homeostasis, and understanding of molecular processes underpinning this can open opportunities for targeted vaccine and immunosuppressive therapeutics, currently little is known about what biological pathways LC use for directing tolerogenic T cell immune responses. Even though some comparisons can be drawn from analysis of other tolerogenic dendritic cell subsets, LC transcriptional programming is distinct from both dendritic cells and macrophages 19, 20, 5, 21 . Thus, in-depth analysis of human primary LCs is necessary to expand understanding of their ability to induce tolerogenic responses. Here, we used single cell RNA-seq and in vitro experimentation to advance understanding of LC heterogeneity and immune activation at both the steady-state and after migration, revealing important insights into how LCs mediate tolerogenic T cell responses at the epidermis. PBMCs were extracted from human blood using lymphoprep (Stemcell, UK) density gradient separation. Naïve T cells were purified using the Naïve CD4+ T cell isolation kit (Miltenyi Biotec, UK). TRMs were extracted from epidermal sheets after 48 hour migration, followed by density gradient separation (Optiprep 1:3).
Methods

Human LC and PBMC isolation:
Flow cytometry/ FACS: Antibodies used for cell staining were pre-titrated and used at optimal concentrations. A FACS Aria flow cytometer (Becton Dickinson, USA) and DIVA software was used for analysis. For FACS purification LCs were stained for CD207 (anti-CD207 PeVio700), CD1a (anti CD1a VioBlue) and HLA-DR (anti-HLA-DR Viogreen, Miltenyi Biotech, UK). For T cell staining, antibodies anti-CD3 PerCP, anti-CD4 Viogreen, anti-CD127 Pe (Miltenyi Biotech, UK) and anti-CD25 PeCy7 (Invitrogen, UK) were used for surface staining. Anti-FOXP3 (FITC, eBiosciences, UK), anti-IL-10 (PE, Miltenyi, UK) and anti-IDO1 (AlexaFluor647, Biolegend, UK) anitbodies were used for intranuclear and intracellular staining. For co-culture assays, purified LC   and naïve CD4+ T cells or TRMs were co-cultured in human serum supplemented   media (RPMI, Gibco, UK, 10% human serum, Sigma, UK, 100 IU/ml penicillin and 100 mg/ml streptomycin, Sigma, UK) at a 1:50 ratio for 5-days at 37°C. For intranuclear RNA-sequencing data are available at GEO under accession number GSE142298.
Co-culture, suppression and inhibition assays:
Results
Steady state LCs exist in a spectrum of immune activation from immaturity to immunocompetency.
LCs in steady-state healthy skin have been shown to expand skin resident memory Tregs which are important for mediating immune homeostasis and preventing unwarranted inflammatory responses 9 . However, when compared to dexamethasone and vitamin D3 stimulated model tolerogenic dendritic cells (TolMoDC), trypsinised steady-state LC display unique upregulated biological pathways with no crossover of differentially expressed genes (DEGs) when compared to unstimulated TolMoDC (FigureS1A, Figure S1B , Supplementary table 1A) . To explore the gene expression profiles underlying healthy LC tolerogenic function and to evaluate population heterogeneity in situ we performed single cell RNAseq on "steady-state LC" dissociated from healthy skin using the dispase/liberase protocol, as published previously 27, 28 . UMAP dimensionality reduction analysis of 607 steady-state LCs revealed heterogeneity was present amongst the population, with LCs transitioning from one state to another ( Figure 1A ). Using hierarchical clustering, steady-state LCs were grouped into two defined clusters (S1 and S2) which separated the population along the transitional route ( Figure 1B ). Gene expression comparison after grouping genes into intervals of increasing expression level, revealed S2 LCs to be more transcriptionally active than S1 ( Figure 1C ). Whilst the most highly expressed genes (>10 normalised expression) in both sub populations were associated with antigen processing and presentation, the number of genes and range of expression was highest at all expression intervals in S2 LCs. Differentially expressed gene (DEG) analysis identified 21 upregulated genes (CD74, HLA-DRA, HLA-DRB1, B2M) in S2 LCs compared to S1 LCs, although no DEGs were identified in S1 compared to S2
( Supplementary table 2A ). Whilst no specific gene ontologies were associated with tolerogenic pathways, analysis revealed associations with MHC II antigen presentation, T cell co-stimulation and response to cytokines ( Figure 1D ). Overall, steady-state LCs appear to exist in a spectrum of activation from lowly activated immature LC (S1) to more highly activated immunocompetent LC (S2), which likely influences their potential for coordinating T cell responses.
Steady state immunocompetent LCs are superior at inducing FOXP3+ Treg
As activation status defined LC subpopulations in the steady-state, the expression of classical DC activation markers and LC markers amongst the population was interrogated (Figure 2A , Figure S2A ). Whilst CD83 expression appeared homogenous, CD40 was lowly detected in all steady-state LC. High HLA-DRA expression was detected in LCs from both clusters but CD86 was predominantly expressed in S2 LC only. Following confirmation of the differential expression at the protein level using flow cytometry, CD86 was selected as a marker for distinguishing the two populations: immunocompetent and immature LCs ( Figure 2B ). To investigate the immune potential of these two steady-state LC populations, CD86High and CD86Low expressing LCs were isolated using FACS ( Figure 2B ) and co-cultured with CD4+ naïve T cells for 5-days after which the expansion of CD25+FOXP3+ Tregs was quantified ( Figure 2C , Figure S2B ). Suprisingly, CD86Low immature LCs did not increase the number of CD4+CD25+FOXP3+ regulatory T cells compared to control.
In contrast, CD86High immunocompetent LC significantly expanded the number of CD25+FOXP3+ Tregs compared to control (p=0.0143) and CD86Low LC (p=0.0129, n=3 independent skin donors), revealing that the state of immunocompetence associates with LC ability to promote T cell-mediated immune tolerance.
Migration enhances tolerogenic abilities of immunocompetent LCs
To explore further the link between LC activation status and tolerance induction, we sought to investigate the effect of in vitro migration from epidermal sheets on LCs tolerogenic characteristics and their molecular profile. We and others have previously shown that LCs, which have migrated out of the epidermis are more immune activated and primed to mediating T cell responses 6, 27, 28 . Therefore, we sought to compare the capability of both steady-state LC and migrated LC to prime naïve CD4 T cells towards a tolerogenic phenotype. The expansion of CD25+FOXP3+ Tregs was measured after 5-day co-culture of naïve CD4+ T cells with LCs extracted at the steady-state via 2 hour enzymatic digestion or through migration from epidermal explants ( Figure 3A ). Figure S4A ). Upregulated genes in migrated LC included CD83 and HLA-DRA as well as CCR7 and IRF4, which have been highlighted as key regulators of LC migration and activation 27, 28 . Upregulation of CD86 was also seen in migrated LC compared to both steady-state LC clusters ( Figure   4C ), validating their highly immunocompetent status.
Steady
To further understand the transcriptional programmes unique to the 3 LC states, differentially expressed genes were identified in pairwise comparisons (Limma, FDR corrected p-value<0.05, LogFC>1, Supplemetary table 3A) . 98 upregulated DEGs were identified comparing migrated to S1, 59 upregulated genes were identified through comparing migrated to S2. 43 upregulated DEGs were identified comparing S2 to migrated further highlighting the switch in gene expression induced after migration. Interestingly, almost all of the DEGs identified between migrated and S2 LCs were also found among the DEGs between migrated and S1 LCs ( Figure S4B) suggesting that immature LCs in S1 could potentially develop immunocompetence, when stumulated. Ontology analysis (ToppGene, FDR corrected p-value<0.05) for DEGs upregulated in S2 compared to migrated included T cell receptor signalling and response to cytokine, suggesting some immune pathways were downregulated after LC migration ( Figure S4C ). However both migrated LC upregulated DEG lists found associations with response to cytokine, and MHC I antigen presentation, highlighting the increased activation of migrated LC compared to steady-state subsets ( Figure 4D and Figure S4D ). Interestingly, DEGs between migrated and S2 revealed specific associations with cell migration, regulation of dendritic cell differentiation and, importantly, T cell tolerance induction ( Figure 4D ). While IDO1 was expressed only in selected steady-state cells, and was not different between S1 and S2 populations, our analysis identified differential upregulation of LGALS1 and AHR in S2 ( Figure 4C ).
LGALS1 (galectin-1) has been broadly associated with the control of a wide range of innate and adaptive immune pathways including maintenance of foetal-maternal tolerance 29, 30 , and AHR has been shown as an important transcription factor involved in IDO1 signalling in IDO1 signalling in DCs 31, 32, 33 , corroborating the importance of IDO1 for LC immunotolerance.
LC-induced tolerance is mediated by IDO1 and can be enhanced by immunotherapeutic intervention.
Among all potential mediators of immunotolerance in immunocompetent LCs, IDO1
was the most extensively expressed in migrated LC, and homogenous in this population. Consistent with the single cell RNA-seq data, the level of IDO1 protein expression was considerably and significantly higher in migrated LCs compared to steady-state LC ( Figure 5A , Figure S5A , n=5 independent skin donors, p=0.0002), indicating that this molecule can be critical to migrated LC tolerogenic function.
Blocking of IDO1 signalling with NLG-919, an immune checkpoint inhibitor, significantly impaired LCs ability to expand tolerogenic T cells ( Figure 5B , p=0.0354).
Interestingly, interference with IDO1 using epacadostat (EPAC), another selective inhibitor of tryptophan catabolism was less potent ( Figure 5B, p=0 .0583). LCs ability to prime and expand tolerogenic T cells creates an exciting opportunity for therapeutic interventions. Since steady-state LCs exist in a spectrum of immunocompetence, with a subpopulation of LCs already poised for tolerance induction, we hypothesised that in situ treatment can further potentiate their tolerogenic behaviour upon migration. To test this, we treated LCs with dexamethasone during migration from the epidermis.
Indeed, dexamethasone migrated LCs were significantly more potent in expanding CD25+FOXP3+ Tregs ( Figure 5C , n=4 independent skin donors, p=0.0271) in comparison to their untreated migrated counterparts. Additionally, CD4+ T cells expanded by migratory DexLCs (n=5 independent skin donors, p=0.0061) produced more IL10 than untreated migrated LC (p=0.028), consistent with their tolerogenic phenotype ( Figure 5D ). Importantly, the presence of dexamethasone during LC migration further increased the expression of IDO1 protein and therefore enhanced the tolerogenic LC phenotype (n=4 independent skin donors, p=0.0142), supporting the importance of IDO1 for LC tolerogenic function ( Figure 5A , Figure S5A ).
Discussion
While LC-mediated immunotolerance appears critical for cutaneous and systemic immune homeostatis, research into molecular mechanisms initiating and maintaining tolerogenic behaviour in human LCs has been significantly affected by the lack of appropriate experimental models and limitations of available technologies. Here, we applied a microfluidic-based single cell and single bead co-encapsulation (Drop-seq, 22 ) followed by high throughput sequencing of individual transcriptomes, to investigate transcriptional programmes in human LCs. This method allowed us to document heterogeneity in steady-state LC transcriptomes, displaying a spectrum of immune activation, previously, to the best of our knowledge, unobserved. Within this spectrum two subpopulations of steady-state LC could be identified: S1, characterised by low RNA content and immature state, and S2, which could be distinguished by high levels of CD86 expression at both mRNA and protein level, and displayed upregulated expression of antigen presenting genes, T cell co-stimulatory genes and genes generally associated with innate immune responses. Surprisingly, this latter population of LCs was characterised by ability to induce a tolerogenic T cell phenotype. Studies have previously shown that DCs in an immature and lowly activated state, expressing low levels of antigen presenting and co-stimulatory molecules, can drive tolerogenic responses by inducing anergy of antigen-specific T cells and expanding Tregs 34, 35 .
However, consistent with our findings, a study by Yamazaki et al. demonstrated that mature CD86High DCs were able to expand CD4+CD25+ T cells more effectively than CD86Low immature DCs 36 . Similarly, epicutaneous immunisation of mice increased migratory LC expression of CD80 and CD86 signature markers of activation, but did not result in efficient generation of effector memory CD4 T cells 37 . Our results indicate that while low expression levels of co-stimulatory molecules on immature DC reported by others may result in impaired generation of T cell activation, induction of tolerance requires delivering of efficient signal 2 through co-stimulation. Indeed, a study of transcriptional determinant of tolerogenic and immunogenic states in murine dendrtic cells, highlighted that DC core antigen presentation module is overlayed by regulatory programmes in a tolerance-induction setting 38 . Supporting the association between immunocompetence and ability to induce tolerance, LC migration out of the epidermis resulted in an even greater ability to induce Tregs than immunocompetent (S2) steadystate LCs. Analysis of single LC transcriptomes confirmed that migratory LCs are mature and characterised by upregulation of MHC II molecules, co-stimulatory molecules (CD80 and CD86) and chemokine receptors (CCR7), indicating readiness for migration to local lymph nodes, mediating interaction with T cells to promote adaptive immune responses 39, 40, 41, 19, 27, 28 .
The increase in T cell co-stimulatory genes, such as CD86 and MHC class II genes in the immunocompetent S2 cluster, and in migrated LCs, suggest that physical interaction with T cells is necessary for LCs to coordinate Treg induction. Indeed, CD86 activity itself has been implicated in DC-mediated tolerance induction through interaction with CTLA4 receptors on T cells 42, 43 . However, since LC ability to induce tolerogenic responses is greatly enhanced with immunocompetence status upon migration, it is likely to be governed by additional factors complementing immune activation, the capacity to process and present antigen and interact with T cells via costimulatory molecules. Indeed, in parallel to LC maturation, in migrated LCs we observed expression of inducible genes previously implicated in tolerance, including IDO1, LGALS1 and AHR. IDO1 is a classical tolerogenic mediator, which catabolises tryptophan leading to skewing of T cell differentiation towards Tregs 44 . Identified as an interferon stimulated gene (ISG), IDO1 has been previously associated with DC activation by IFNs and TNF-a 45, 46 and has been implicated in a number of regulatory feedback loops in cross-talk with other cell types -e.g. activation of CTLA4 receptors on T cells in turn induces IDO1 expression in DCs 43 . Two studies in human LCs previously demonstrated induction of IDO1 steady-state LCs, and its importance for inhibition of effector T cell proliferation on stimulation with IFN-g 47 and for FceRI signalling 33 . Our study confirms and extends these findings, highlighting IDO1 as a key regulator of LC tolerogenic responses induced during LC migration, which is amenable to modulation, e.g. through treatment with dexamethasone, and suggests a progression of LC tolerogenic abilities from low/poised in S2, associated with transcript expression of AHR, to fully competent in migrated LC, mediated through high levels of IDO1 protein. Consistently, steady-state LCs, which do not express high levels of IDO1, have limited ability to activate regulatory T cells, are perhaps sufficient to maintain tolerogenic memory T cells in situ. In contrast, high levels of IDO1 induced by migration promote LC ability to prime naïve T cells for tolerance towards autoantigens. Sequential expression of AHR followed by IDO1 upon migration provides a mechanism for inducible IDO1 expression upon activation, and suggests the existence of a reinforcement loop for in situ tolerogenic responses through AHR signalling. This was previously observed in other DCs, where kynurenine metabolites, produced during IDO-mediated catabolism of tryptophan, feedback to AHRs to sustain IDO expression 31, 32 .
Our extensive analysis of human primary steady-state and migrated LCs indicates that while LCs with tolerogenic ability exist in situ, migration greatly enhances LC tolerogenic potential, likely through induction of IDO1. IDO1 dependence on proinflammatory and activatory signals makes it a compelling candidate as a regulator of immune activation and immune tolerance in LCs, preventing excessive activation and mediating cutaneous homeostasis. The enhancement of LC tolerogenic abilities on maturation could be explored therapeutically to reinstate tolerance in the skin during inflammatory conditions.
Figure Legends Figure 1. Steady state LCs exist in a spectrum of immune activation from immaturity to immunocompetency
A. UMAP plot of 607 steady-state LCs (Scater, R) from 1769 genes following filtering (mitochondrial genes <0.2) and SCnorm normalisation. B. Hierarchical clustering (clust=ward.D2, dist=canberra) of steady-state LCs defining the division of the population into two sub clusters, steady-state 1 (S1) and steady-state 2 (S2). C. S1 and S2 normalised gene expression values were grouped into expression level intervals (y-axis). The number of genes included in each interval and the top associated biological processes identified using ToppGene gene ontology analysis are displayed with significance values (FDR corrected p-value). D. Gene ontology analysis using ToppGene of 21 DEGs upregulated in S2 LC compared to S1 LC. -log(10) FDR corrected FDR corrected p-values are displayed. 
Figure S3. Migration enhances tolerogenic abilities of immunocompetent LCs
A. Gating strategy for investigating CFSE labelled PBMC proliferation, selecting for CD4+ and CD8+ T cell populations. CFSE measurement gating was applied to responder cell population only, excluding unlabelled CFSE negative Tregs. B. Gating strategy for investigating the quantity of Tregs induced after co-culture of autologous TRMs with migrated LC for 5-days. 
Figure S5. LC-induced tolerance is mediated by IDO1 can be enhanced by immunotherapeutic intervention.
A. Gating strategy to define the percentage of IDO1 expression in steady-state LC, migrated, and dexamethasone migrated LC. n=5 steady-state and migrated LC experiments, n=4 migrated dexamethasone experiments.
Supplementary Table 1. Trypsinised steady-state LC and TolMoDC DEGs
A. DEGs comparing trypsined steady-state LC to unstimulated MoDC (GSE23618) and TolMoDC to unstimulated MoDC (GSE52894) were indentified using Limma (FDR corrected p-value<0.05, logFC>1). Biological pathways associated with DEGs were identified in Toppgene (FDR corrected p-value<0.05).
